Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?

Pharmacology and Toxicology

Volumn 82, Issue 6, 1998, Pages 257-271

  De Gasparo, Marc ^a   Levens, Nigel ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PHOSPHATASE; VALSARTAN;

CELL GROWTH; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG TARGETING; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; HYPERTENSION; KIDNEY FAILURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0031831020     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01572.x     Document Type: Short Survey

References (188)

1. Alderman, C. P.: Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacotherap. 1996, 30, 55-61.
2. Ali, M. S., P. P. Sayeski, L. B. Dirksen, D. J. Hayzer, M. B. Marrero & K. E. Bernstein: Fdependence of the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT(1) receptor. J. Biol. Chem. 1997, 272, 23382-23388.
3. Allen, T., U. L. Hulthen, Z. Cao & M. E. Cooper: Albuminuria in experimental diabetes: role of angiotensin and bradykinin. Diabetes 1996, 45, Suppl 2; 3A.
4. Allen, T. J., Z. Cao, U. L. Hulthen & M. E. Cooper: The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997, 46, 1612-1618.
5. Anderson, S., H. G. Rennke & B. Brenner: Therapeutic advantage of converting enzyme in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986, 77, 1993-2000.
6. Azizi, M., G. Chatellier, T. T. Guyene, D. Murietageoffroy, & J. Ménard: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin ii antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92, 825-834.
7. Azizi, M., A. Rousseau, E. Ezan, T. T. Guyene, S. Michelet, J. M. Grognet, M. Lenfant, P. Corvol & J. Ménard: Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator n-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996, 97, 839-844.
8. Azuma, H., Y. Niimi & H. Hamasaki: Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin-II receptor antagonist, losartan. Brit. J. Pharmacol. 1992, 106, 665-671.
9. Balcells, E., Q. C. Meng, G. R. Hageman, R. W. Palmer, J. N. Durand & L. J. Dell Italia: Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Amer. J. Physiol. 1996, 271, H417-H421.
10. 1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure. Circulation 1996, 94, I-428.
11. Bedecs, K., N. Elbaz, M. Sutren, M. Masson, C. Susini, A. D. Strosberg & C. Nahmias: Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem. J. 1997, 325, 449-454.
12. Benter, I. F., D. I. Diz & C. M. Ferrario: Cardiovascular actions of angiotensin(1-7). Peptides 1993, 14, 679-684.
13. Berk, B. C. & M. A. Corson: Angiotensin II signal transduction in vascular smooth muscle - role of tyrosine kinases [review]. Circ. Res. 1997, 80, 607-616.
14. Bernstein, K. E.: The renin-angiotensin system: a biological machine. Ann Med. 1993, 24, 113-115.
15. Bernstein, K. E. & M. B. Marrero: The importance of tyrosine phosphorylation in angiotensin II signaling. Trends Cardiovasc. Med. 1996, 6, 179-187.
16. Bleuel, A., M. de Gasparo, S. Whitebread, I. Puttner & D. Monnard: Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors. J. Neurosci. 1995, 15, 750-761.
17. 2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem. Biophys. Res. Commun. 1992, 183, 206-211.
18. 2 receptor in PC12W cells. Regul. Pept. 1993, 44, 207-213.
19. Brosnihan, K. B., P. LI & C. M. Ferrario: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996, 27, 523-528.
20. Buehlmayer, P.: Angiotensin II antagonists: patent activity since the discovery of DuP-753. Curr. Opin. Ther. Patents 1993, 2, 1693-1718.
21. Buisson, B., L. Laflamme, S. P. Bottari, M. deGasparo, N. Gallopayet & M. D. Payet: A G protein is involved in the angiotensin AT(2) receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells. J. Biol. Chem. 1995, 270, 1670-1674.
22. Bumpus, F. M., H. Schwarz & I. H. Page: Synthesis and pharmacology of the octapeptide angiotonin. Science 1957, 125, 886-887.
23. Bunkenburg, B., C. Schnell, H. P. Baum, F. Cumin & J. M. Wood: Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension 1991, 18, 278-288.
24. Burnier, M., M. Hagman, J. Nussberger, J. Biollaz, C. Armagnac, R. Brouard R. B. Waeber & H. R. Brunner: Short-term and sustained renal effects of angiotensin IIii receptor blockade in healthy subjects. Hypertension. 1995, 25, 602-609.
25. Burnier, M., F. Rochramel & H. R. Brunner: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996, 49, 1787-1790.
26. 1 subtype angiotensin receptor antagonist. J. Pharmacol. Exp. Therap. 1993, 265, 826-834
27. Chai, S. Y. & C. I. Johnston: Tissue distribution of angiotensin-converting enzyme. In: Hypertension: Pathophysiology, diagnosis, and management. Eds.: J. H. Laragh and B. M. Brenner. Raven Press Ltd. New York, 1995, 1683-1694.
28. Chan, D. P., E. K. Sandok, L. L. Aarhus, D. M. Heublein & J. C. Burnet, Jr.: Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. Amer. J. Hypertens. 1992, 5, 354-360.
29. Chiu, A. T. & M. J. Peach: Inhibition of induced aldosterone biosynthesis with a specific antagonist of angiotensin II. Proc. Natl. Acad. Sci. USA. 1974, 71, 341-344.
30. Cigola, E., J. Kajstura, B. Li, L. G. Meggs & P. Anversa: Angiotensin II activates programmed myocyte cell death in vitro. Exp. Cell Res. 1997, 231, 363-371.
31. Clauser, E. L., K. M. Curnow, S. Conchon, E. Davies, B. Teutsch, B. Vianello, C. Monnot & P. Corvol: Molecular structure and mechanisms of action of mammalian angiotensin II receptors. Curr. Opin. Endocrinol. Diabetes 1995, 2, 404-411.
32. Corea, L., O. Cardoni, R. Fogari, P. Innocenti, C. Porcellati, M. Provvidenza, S. Meilenbrock, J. Sullivan & F. Bodin: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension - A comparative study of the efficacy and safety against amlodipine. Clin. Pharmacol. Therap. 1996, 60, 341-346.
33. Criscione, L., W. A. Bradley, P. Buehlmayer, S. Whitebread, R. Glazer, P. Lloyd, P. Mueller & M. de Gasparo: Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc. Drug Rev. 1995, 13, 230-250.
34. Crozier, I. & H. Ikram: The acute and chronic effects of losartan in heart failure. J. Hypertens. 1995a, 13, S 59-S 61.
35. Crozier, I., H. Ikram, N. Awan, J. Cleland, N. Stephen, K. Dickstein, M. Frey, J. Young, G. Klinger, L. Makris & E. Rucinska: Losartan in heart failure - hemodynamic effects and tolerability. Circulation 1995b, 91, 691-697.
36. deBlois, D., B. S. Tea, V. D. Than, J. Tremblay & P. Hamet: Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997, 29, 340-349.
37. de Gasparo, M., St. Whitebread, N. Levens, H. P. Ramjoué, L. Criscione, H. Rogg, H. P. Baum, V. Brechler, P. Buehlmayer, J. M. Wood & S. Bottari: Pharmacology of angiotensin II receptor subtypes. In: Cellular and molecular biology of the adrenal cortex. Eds.: J. M. Saez, A. C. Brownie, A. Capponi, E. M. Chambaz & F. Mantero, John Libbey Eurotext Ltd., 1992, pp. 3-17.
38. 2 in human myometrium during pregnancy. Regul. Pept. 1994, 53, 39-45.
39. de Gasparo, M., S. Bottari & N. R. Levens: Characteristics of angiotensin II receptors and their role in cell and organ physiology. In: Hypertension: Physiology, diagnosis, and management. Eds.: J. H. Laragh and B. M. Brenner. Raven Press: New York, Ltd. 1995a, 1695-1720.
40. de Gasparo, M., A. Husain, W. Alexander, K. J. Catt, A. T. Chiu, M. Drew, T. Goodfriend, J. W., Harding, T. Inagami & P. B. M. W. M. Timmermans: Proposed update of angiotensin receptor nomenclature. Hypertension 1995b, 25, 924-927.
41. Demeilliers, B., B. Jover & A. Mimran: Renal function in one-kidney, one clip sodium-restricted rats: influence of enelapril and losartan. J. Hypertens. 1995, 13, 1764-1766.
42. Dubey, R. K., E. K. Jackson & T. F. Luscher: Nitric oxide inhibits angiotensin II induced migration of rat aortic smooth muscle cell - Role of cyclic nucleotides and angiotensin receptors. J. Clin. Invest. 1995, 96, 141-149.
43. Dzau, V. J. & G. H. Gibbons: Autocrine-paracrine mechanisms of vascular myocytes in sytemic hypertension. Amer. J. Cardiol. 1987, 60, 991-1031.
44. Dzau, V. J.: Implications of local angiotensin production in cardiovascular physiology and pharmacology. Amer. J. Cardiol. 1987, 59, 59A-65A.
45. Dzau, V. J.: Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J. Hypertens. 1989, 7, 933-936.
46. Dzau, V. J., G. H. Gibbons & R. E. Pratt: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991, 18 (suppl II), 100-105.
47. Dzau, V. J. & M. Horiuchi: Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis. Eur. Heart J. 1996, 17, 978-980.
48. Eggena, P., J. H. Zhu, K. Clegg & J. D. Barrett: Nuclear angiotensin receptors induce transcription of renin and angiotensinogen messenger RNA. Hypertension 1993, 22, 496-501.
49. Fauvel, J. P., S. Velon, N. Berra, N. Pozet, O. Madonna, P. Zech & M. Laville: Effects of losartan on renal function in patients with essential hypertension. J. Cardiovasc. Pharmacol. 1996, 28, 259-263.
50. Faxon, D. P.: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the Marcator study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multiple American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J. Amer. Coll. Cardiol. 1995, 25, 362-369.
51. Fornes, P., C. Richer, E. Vacher, P. Bruneval & J. F. Giudicelli: Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J. Cardiovasc. Pharmacol. 1993, 22, 305-313.
52. Fossa, A. A., M. J. DePasquale, L. J. Ringer & R. L. Winslow: Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin ii receptor antagonist. Drug Dev. Res. 1994, 33, 422-428.
53. 2 receptor down-regulates neurofilament in PC12W cells. Neurosci. Lett. 1997, 227, 29-32.
54. Gallinat, S., M. H. Yu, Y. Z. Zhu, T. Herdegen & Th. Unger: Upregulation of angiotensin receptors after myocardial infarction and sciatic nerve transection: a common expression pattern. Hypertension 1997, 30, 999.
55. Gansevoort, R. T., D. Dezeeuw, S. Shahinfar, A. Redfield & P. E. Dejong: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J. Hypertens. 1994, 12, S 37 S 42.
56. Gavras, I. & H. Gavras H: Captopril and enalapril (letter). Ann. Intern. Med. 1983, 98, 556-557.
57. Giasson, E., M. J. Servant & S. Meloche: Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with supression of tyrosine phosphorylation signalling in vascular smooth muscle cells. J. Biol. Chem. 1997, 272, 26879-26886.
58. Gillis, J. L. & A. Markham: Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997, 54, 885-902.
59. Goa, K. L. & A. J. Wagstaff: Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996, 51, 820-845.
60. Gohlke, P., V. Lamberty, I. Kuwer, S. Bartenbach, A. Schnell, W. Linz, B. A. Scholkens, G. Wiemer & T. Unger: Long-term low-dose angiotensin converting enzyme inhalation treatment increases cycle guenosine 3′5′-monophosphate. Hypertension 1993, 22, 682-687.
61. Gohlke, P., W. Linz, B.A. Scholkens, G. Wiemer & T. Unger: Cardiac and vascular effects of long-term treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996, 28, 397-402.
62. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998, 31, 349-355.
63. Goldberg, A. I., M. C. Dunlay & C. S. Sweet: Safety and tolerability of losartan potassium, and angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Amer. J. Cardiol. 1995a, 75, 793-795.
64. Goldberg, M. R., T. E. Bradstreet, E. J. Mcwilliams, W. K. Tanaka, S. Lipert, T. D. Bjornsson, S. A. Waldman, B. Osborne, L. Pivadori, G. Lewis, R. Blum, T. Herman, P. A. Abraham, C. N. Halstenson, M. W. Lo, H. Lu & R. Spector: Biochemical effects of losartan, a nonpeptide angiotensinII receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995b, 25, 37-46.
65. Goldfarb, D. A., D. I. Diz, R. R. Tubbs, C. M. Ferrario & A. C. Novick: Angiotensin-II receptor subtypes in the human renal cortex and renal cell carcinoma. J. Urol. 1994, 151, 208-213.
66. Goodfriend, T. L., M. E. Elliott & K. J. Catt: Drug therapy angiotensin receptors and their antagonists [review]. New. Engl. J. Med. 1996, 334, 1649-1654.
67. Goto, M., M. Mukoyama, S. Suga, T. Matsumoto, M. Nakagawa, R. Ishibashi, M. Kasahara, A. Sugawara, I. Tanaka & K. Nakao: Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997, 30, 358-362.
68. Gottlieb, S. S., K. Dickstein, E. Fleck, J. Kostis, T. B. Levine, T. Lejemtel & M. Dekock: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993, 88, 1602-1609.
69. 2 receptors in the developing rat fetus. J. Clin. Invest. 1991, 88, 921-933.
70. Griendling, K. K., T. J. Murphy & R. W. Alexander: Molecular biology of the renin-angiotensin system. Circulation 1993, 87, 1816-1828.
71. Griendling, K. K., B. Lassègue & R. W. Alexander: Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 281-306.
72. Griendling, K. K., M. Ushiofukai, B. Lassegue & R. W. Alexander: Angiotensin II signaling in vascular smooth muscle New concepts. Hypertension 1997, 29, 366-373.
73. Griffin, S. A., W. C. Brown, F. MacPherson, J. C. McGrath, V. G. Wilson, N. Korsgaard, M. J. Mulvany & A. F Lever: Angiotensin II causes vascular hypertrophy in part by a non-pressore mechanism. Hypertension 1991, 17, 626-635.
74. Hagiwara, H., N. Sugiura, K. I. Wakita & S. Hirose: Purification and characterization of angiotensin-binding protein from porcine liver cytosolic fraction. Eur. J. Biochem. 1989, 185, 405-410.
75. Handa, R. K., C. M. Ferrario & J. W., Strandhoy: Renal actions of angiotensin (1-7): in vivo and in vitro studies. Amer. J. Physiol. 1996, 270, F141-F147.
76. Harding, J. W., J. W. Wright, G. N. Swanson, J. M. Hanesworth & L. T. Krebs: AT(4) receptors - specificity and distribution. Kidney Int. 1994, 46, 1510-1512.
77. Harton, P., K. Engels & C. Baylis: Differing renovascular responses to three methods of angiotensine II (AII) blockade. J. Amer. Soc. Hephol. 1991, 2, 402 (abstract).
78. Holland, O. B.: Angiotensin II receptors. Curr. Opin. Endocrinol. Diabetes 1996, 3, 258-264.
79. Horiuchi, M., W. Hayashida, T. Kambe, T. Yamada & V. J. Dzau: Angiotensin type 2 receptor dephosphorylate Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J. Biol. Chem. 1997, 272, 19022-19026.
80. Huang, X. C., E. M. Richards & C. Sumners: Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type I receptors and inhibited by angiotensin II type 2 receptors. J. Biol. Chem. 1996, 271, 15635-15641.
81. Inada, Y. T. Wada, M. Ojima, T. Sanada, Y. Shibouta, R. Kanagawa, Y. Ishimura, Y. Fujiwasa & K. Nishikawa: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 1997, 19, 1079-1099.
82. Inagami, T., D. Fuo & Y. Kitami: Molecular biology of angiotensin II receptors: an overview. J. Hypertens. 1994, 12 (suppl. 10), S83-S94.
83. Jaiswal, N., D. I. Diz, M. C. Chappell, M. C. Khosla & C. M. Ferrario: Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 1992, 19, II49-II55.
84. Janiak, P., A. Pillon, J. F. Prost & J. P. Vilaine: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992, 20, 737-745.
85. Jenkins, A. C., G. R. Dreslinski, S. C. Tadros, J. T. Groel, R. Fand & S. A. Herszeg: Captopril in hypertension: seven years later. J. Cardiovasc. Pharmacol. 1985, 7, S96-S101.
86. Johnson, M. C. & A. Aguilera: Angiotensin II receptor subtypes and coupling to signaling systems in culture foetal fibroblasts. Endocrinology 1991, 129, 1261-1274.
87. Jover, B. & A. Mimran: Angiotensin II receptor antagonists versus angiotensin-converting enzyme inhibitors effects on renal function. J. Hypertens. 1994, 12, S 3-S 9.
88. Kambayashi, Y., S. Bardhan, K. Takahashi, S. Tsuzuki, H. Inui, T. Hamakubo & T. Inagami: Molecular cloning of a novel angiotensin-II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268, 24543-24546.
89. Kamper, A. L., S. Strandgaard & P. P. Leyssac: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Amer. J. Hypertens. 1992, 5, 423-430.
90. Kang, J., E. M. Richards, P. Posner & C. Sumners: Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment. Amer. J. Physiol. 1995, 37, C 278-C282.
91. Kauffman, R. F., J. S. Bean, K. M. Zimmerman, R. F. Brown & M. I. Steinberg: Losartan, a nonpeptide angiotensin II receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci. 1991, 49, 223-228.
92. Kerins, D. M., Q. Hao Q & D. E. Vaughn: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J. Clin. Invest. 1995, 96, 2515-2520.
93. Kim, S. K., K. Ohta, A. Hamaguchi, T. Omura, T. Yukimura, K. Miura, Y. Inada, T. Wada, Y. Ishimura, F. Chatani & H. Iwao: Ccontribution of renal angiotensin II typel receptor to gene expressions in hypertension-induced renal injury. Kidney Int. 1994, 46, 1346-1358.
94. Kim, S. K., K. Ohta, A. Hamaguchi, T. Omura, T. Yukimura, K. Miura, Y. Inada, Y. Ishimura, F. Chatani & H. Iwao: Angiotensin II type I receptor antagonists inhibit the gene expression of transforming growth factor-beta-1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J. Pharmacol. Exp. Therap. 1995, 273, 509-515.
95. Komers, R. & M. E. Cooper: Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Amer. J. Physiol. 1995, 268, F588-F594.
96. Kometani, M., N. Hayashi, S. Yamamoto, K. Nakao & T. Inukai: Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. Valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment. Arzneimittelforsch./Drug Res. 1997, 47, 613-619.
97. Kon, V., A. Fogo & I. Ichikawa: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993, 44, 545-550.
98. Lafayette, R. A., G. Mayer, S. K. Park & T. W. Meyer: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1992, 90, 766-771.
99. Laflamme, L., M. de Gasparo, J. M. Gallo, M. D. Payet & N. Gallopayet: Angiotensin II induction of neurite outgrowth by AT(2) receptors in NG108-15, cells - Effect counteracted by the AT(1) receptors. J. Biol. Chem. 1996, 271, 22729-22735.
100. Laporte, S. & E. Escher: Neointima formation after vascular injury is angiotensin II mediated. Biochem. Biophys. Res. Commun. 1992, 187, 1510-1516.
101. Ledingham, J. M. & R. Laverty: Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin. Exp. Pharmacol. Physiol. 1996, 23, 576-578.
102. Lehtonen, J. Y., W. Hayashida, M. Horiuchi & V.J. Dzau: Angiotensin II receptor subtype specific effects are mediated by intracellular third loops: chimeric receptor approach. Circulation 1997a, 96, suppl. 1, I-478 (abstract 2667).
103. Lehtonen, J. Y., M. Horiuchi & V. J. Dzau: Ceramide as a second messanger for angiotensin II type 2 receptor mediated apoptosis. Circulation 1997b, 96, suppl. 1, I-554 (abstract 3099).
104. Levens, N. R., M. de Gasparo, J. M. Wood & S. Bottari: Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin convering enzyme be clinically beneficial? Pharmacology & Toxicology 1992, 71, 241-249 (Mini Review).
105. Levy, B. I., J. Benessiano, D. Henrion, L. Caputo, C. Heymes, M. Duriez, P. Poitevin & J. L. Samuel: Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J. Clin. Invest. 1996, 98, 418-425.
106. 2 angiotensin receptor antagonism on blood pressure and small artery structure in angiotensin II-infused rats. Circulation 1997, 96, suppl. 1, I-477 (abstract 2666).
107. Liu, Y. H., X. P. Yang, V. G. Sharov, O. Nass, H. N. Sabbah, E. Peterson & O. A. Carretero: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - role of kinins and angiotensin II type 2 receptors. J. Clin. Invest. 1997, 99, 1926-1935.
108. Lopez, J. J., B. H. Lorell, J. R. Ingelfinger, E. O. Weinberg, H. Schunkert, D. Diamant & S. S. Tang: Distribution and function of cardiac angiotensin AT(1)- and AT(2)-receptor subtypes in hypertrophied rat hearts. Amer. J. Physiol. 1994, 267, H 844-H 852.
109. Mackenzie, H. S., J. L. Troy, H. G. Rennke & B. M. Brenner: TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J. Hypertens. 1994, 12, S 11-S 16.
110. Markham, A. & K. L. Goa: Valsartan - a review of its pharmacology and therapeutic use in essential hypertension [Review]. Drugs 1997, 54, 299-311.
111. Maschio, G., D. Alberti, G. Janin, F. Locatelli, J. F. E. Mann, M. Motolese, C. Ponticelli, E. Ritz, P. Zucchelli, and the Angiotensin-Converting-Enzyme Inhibition in Progresive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. New Engl. J. Med. 1996, 334, 939-945.
112. McWhinney C. D., R. A. Hunt, K. M. Conrad, D. E. Dostal & K. M. Baker: The type I angiotensin II receptor couples to STAT1 and STAT3 activation through JAK2 kinase in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 1997, 29, 2513-1524.
113. Meffert, S., M. Stoll, U. M. Steckeling, S. P. Bottari & T. Unger: The angiotensin II AT(2) receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996, 122, 59-67.
114. Ménard, J., D. J. Campbell, M. Azizi & M. F. Gonzales: Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997, 96, 3072-3078.
115. Mercator Study Group: Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneaous transluminal coronary angioplasty? The results of the Mercator study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992, 86, 100-110.
116. Morimoto, S. & T. Ogihara: TCV-116: a new angiotensin II type-1 receptor antagonist. Cardiovasc. Drug Rev. 1994, 12, 153-164.
117. Mukoyama, M., M. Nakajima, M. Horiuchi, H. Sasamura, R. E. Pratt & V. J. Dzau: Expression cloning of type-2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993, 268, 24539-24542.
118. MunozGarcia, R., R. Maeso, E. Rodrigo, J. Navarro, L. M. Ruilope, M. C. Casal, V. Cachofeiro & V. Lahera: Acute renal excretory actions of liosartan in spontaneously hypertensive rats - role of AT(2) receptors, prostaglandins, kinins and nitric oxide. J. Hypertens. 1995, 13, 1779-1784.
119. Murphy, T. J., R. W. Alexander, K. K. Griendling, M. S. Runge & K. E. Bernstein: Isolation of a cDNA encoding the vascular type-I angiotensin II receptor. Nature 1991, 351, 233-236.
120. Nahmias, C. & A. D. Strosberg: The angiotensin AT(2) receptor -searching for signal-transduction pathways and physiological function. Trends Pharmacol. Sci. 1995, 16, 223-225.
121. Nakajima, M., H. G. Hutchinson, M. Fujinaga, W. Hayashida, R. Morishita, L. Zhang, M. Horiuchi, R. E. Pratt & V. J. Dzau: The angiotensin II type 2 (AT(2)) receptor antagonizes the growth effects of the AT(1) receptor - Gain-of-function study using gene transfer. Proc. Natl. Acad. Sci. USA 1995, 92, 10663-10667.
122. Nio, Y., H. Matsubara, S. Murasawa, M. Kanasaki & M. Inada: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J. Clin. Invest. 1995, 95, 46-54.
123. Nussberger, J., D. Brunner, B. Waeber & H. R. Brunner: True versus immunoreactive angiotensin II in human plasma. Hypertension 1985, 7, I-1-I-7.
124. Oikawa, T., M. Freeman, W. Lo, D. E. Vaughan & A. Fogo: Modulation of plasminogen activator inhibitor-1 in vivo - a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997, 51, 164-172.
125. Okunishi, H., Y. Oka, N. Shiota, T. Kawamoto, K. Song & M. Miyazaki: Marked species-difference in the vascular angiotensin II-forming pathways -human versus rodents. Jap. J Pharmacol. 1993, 62, 207-210.
126. Ondetti, M. A.: Angiotensin-converting enzyme inhibitors: an overview. Hypertension 1991, 18 Suppl. 3, III134-III135.
127. Oparil, S., S. Dyke, F. Harris, J. Kief, D. James, A. Hester & S. Fitzsimmons: The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin. Ther. 1996, 18, 797-810.
128. Ozawa, Y., Y. Suzuki, K. Murakami & H. Miyazaki: The angiotensin II type 2 receptor primarily inhibits cell growth via pertussis-toxin-sensitive G proteins. Biochem. Biophys. Res. Commun. 1996, 228, 328-333.
129. Pals, D. T., G. S. Denning & R. E. Keenan: Historical development of saralasin. Kidney Int. 1979, 15, S7-S10.
130. Peach, M. J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 1977, 57, 313-370.
131. Peach, M. J. & N. R. Levens: Molecular approaches to the study of angiotensin receptors. Adv. Exp. Med. Biol. 1980, 130, 171-191.
132. Pfeffer, M. A.: Angiotensin-converting enzyme inhibition in congestive heart failure benefit and perspective. Amer. Heart J. 1993, 126, 789-793.
133. Pitt, B., R. Segal, F. A. Martinez, G. Meurers, A. J. Cowley, I. Thomas, P. C. Deedwania, D. E. Ney, D. B. Snavely & P. I. Chang: Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, Elite). Lancet 1997, 349, 747-752.
134. Pollman, M. J., T. Yamada, M. Horiuchi & G. H. Gibbons: Vasoactive substances regulate vascular smooth muscle cell apoptosis countervailing influences of nitric oxide and angiotensin II. Circ. Res. 1996, 79, 748-756.
135. 2 isoforms of the angiotensin receptor mediates myointimal hyperplasia following vascular injury. Hypertension 1992, 20, 432-452.
136. 1 receptor antagonist: effects on smooth muscle cells migration and proliferation afyer balloon catheter injury. Amer. J. Pathol. 1991, 139, 1291-1296.
137. Ramjoué, H. P., E. Hermes, V. Nogues V & M. de Gasparo: Valsartan prevents angiotensin II induced cardiac myocyte necrosis. Eur. Heart J. 1994, 15, 567.
138. Regitz-Zagrosek, V., N. Friedel, A. Heymann, P. Bauer, M. Neuss, A. Rolfs, C. Steffen, A. Hildebrandt, R. Hetzer & E. Flek: Regulation, chamber localization and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995, 91, 1461-1471.
139. Regitz-Zagrosek, V., J. Fielitz, R. Dreysse, A. G. Hildebrandt & E. Flek: Angiotensin receptor type 1 mRNA in human right ventricular endomyocardial biopsies downregulation in heart failure. Cardiovasc. Res. 1997, 35, 99-105.
140. Remuzzi, A., N. Perico, C. S. Amuchastegui, B. Malanchini, M. Mazerska, C. Battaglia, T. Bertani & G. Remuzzi: Short-term and long-term effect of angiotensin-II receptor blockade in rats with experimental diabetes. J. Amer. Soc. Nephrol. 1993, 4, 40-49.
141. Remuzzi, A., A. Fassi, F. Sangalli, B. Malanchini & G. Remuzzi: Effect of benazepril and valsartan on glomerular injury in experimental diabetes in MWF/Ztm rats. J. Amer. Soc. Nephrol. 1996, 7, 1877.
142. Riordan, J. F.: Angiotensin II - Biosynthesis, molecular recognition. and signal transduction. Cell. Mol. Biol. 1995, 15, 637-651.
143. Rittel, W., B. Iselin, H. Kappeler, B. Riniker & R. Schwyzer: Synthese eines hochwirksamen Hypertensin II-amid [L-Aparaginyl-L-arginyl-L-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-L-prolyl-L- phenylalanin]. Helv. Chim Acta 1957, 40, 614-619.
144. Rogg, H., M. de Gasparo, E. Graedel, P. Stulz, F. Burkart, M. Eberhard & P. Erne: Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur. Heart J. 1996, 17, 1112-1120.
145. Rydzewski, B., B. Zelezna, W. Tang, C. Sumners & M. K. Raizada: Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology. 1992, 130, 1255-1262.
146. Sasaki, K., Y. Yamano, S. Bardhan, N. Iwai, J. J. Murray, M. Hasegawa, Y. Matsuda & T. Inagami: Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991, 351, 230-233.
147. Scheidegger, K. J., J. M. Wood, H. Vanessen & H. A. J. Struijker-Boudier: Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 1996, 278, 1276-1281.
148. Scheidegger, K. J. & J. M. Wood: Local application of angiotensin II to the rat carotid artery induces adventitial thickening. J. Vasc. Res. 1997, 34, 436-446.
149. Schiavone, M. T., M. C. Khosla & C. M. Ferrario: Angiotensin-(1-7): evidence for novel actions in the brain. J. Cardiovasc. Pharmacol. 1990, 16, Suppl 4, S19-S24.
150. Schieffer, B., W. G. Paxton, M. B. Marrero & K. E. Bernstein: Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Hypertension 1996, 27, 476-480.
151. Sealey, J. E. & J. H. Laragh: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Hypertension: Pathophysiology, diagnosis and management. J. H. Laragh and B. M. Brenner. Raven Press Ltd; Eds.: New York, 1995, 1763-1796.
152. Seljeflot, I., A. Moan, S. Kjeldsen, E. Sandvik & H. Arnesen: Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996, 27, 1299-1304.
153. Sen, I., K. F. Jim & R. L. Soffer: Solubilization and characterization of an angiotensin II binding protein from liver. Eur. J. Biochem. 1983, 136, 41-49.
154. Siragy, H. M. & R. M. Carey: The subtype-2 (AT(2)) angiotensin receptor regulates renal cyclic guanosine 3′,5′-monophosphate and AT(1) receptor-mediated prostaglandin E2 production in conscious rats. J. Clin. Invest. 1996, 97, 1978-1982.
155. Siragy, H. M. & R. M. Carey: The subtype 2 angiotensin receptor regulates renal prostaglandin F2 formation in conscious rats. Amer. J. Physiol. 1997, 273, R1103-R1107.
156. Siragy, H. M. & R. M. Carey: The subtype 2 (AT(2)) Angiotensin receptor mediates renal production of nitric oxide in conscious rats. J. Clin. Invest. 1997, 100, 264-269.
157. Spinale, F. G., M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, M. Melton, S. Krombach, R. Mukherjee & O. Seung-Jun: Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure. I. Effect on left ventricular performance and neurohormonal systems. Circulation 1997a, 96, 2385-2396.
158. Spinale, F. G. R. Mukherjee J. P. Iannini, S. Whitebread, L. Hebbar, M. J. Clair, M. Melton, M. H. Cox, P. B. Thomas & M. de Gasparo: Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure. II. Effects on myocyte contractile processes. Circulation 1997b, 96, 2397-2406.
159. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 1995, 95, 651-657.
160. Swanson, G. N., J. M. Hanesworth, M. F. Sardinia, J. K. Coleman, J. W. Wright, K. L. Hall, A. V. Miller Wing, J. W. Stobb, V. I. Cookm & E. C. Harding: Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul. Pept. 1992, 40, 409-419.
161. Taguchi, J., J. Abe, H. Okazaki, M. Ochiai, M. Ohno, Y. Takuwa & K. Kurokawa: Angiotensin-converting enzyme inhibitors or Dup753 prevent neointimal formation following balloon injury with single topical or multiple systemic application. Biochem. Biophys. Res. Commun. 1993, 196, 969-974.
162. Tan, L. B., J. E. Jalil, R. Pick, J. S. Janicki & K. T. Weber: Cardiac myocyte necrosis induced by angiotensin II. Circulation 1991, 69, 1185-1195.
163. Tang, S. S., H. Rogg, R. Schumacher & V. J. Dzau: Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology 1992, 131, 374-380.
164. Teiger, E., T. Dam, L. Richard, C. Wisnewsky, B. Tea, L. Gaboury, J. Tremblay, K. Schwartz & P. Hamet: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J. Clin. Invest. 1996, 97, 2891-2897.
165. Timmermans, P. B. M. W. M., P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye & R. D. Smith: Angiotensin-II receptors and angiotensin-II receptor antagonists. Pharmacol. Rev. 1993, 45, 205-251.
166. Toto, R., P. Schultz, L. Raji, H. Mitchell, W. Shaw, D. Ramjit, J. Toh & S. Shahinfar: Efficacy anf tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998, 31, 684-691.
167. Unger, T., O. Chung, T. Csikos, J. Culman, S. Gallinat, P. Gohlke, S. Hohle, S. Meffert, M. Stoll, U. Stroth & Y. Z. Zhu: Angiotensin receptors. J. Hypertens, 1996, 14 (suppl. 5), S95-S103.
168. Urata, H., F. Strobel & D. Ganten: Widespread tissue distribution of human chymase. J. Hypertens. 1994, 12, S 17-S 22.
169. Urata, H., H. Nishimura & D. Ganten: Mechanism of angiotensin Il formation in humans. Eur. Heart J. 1995, 16, 79-85.
170. Wada, T., R. Kanagawa, Y. Ishimura, Y. Inada & K. Nishikawa: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J. Hypertens. 1995, 13, 113-122.
171. Waeber, B., J. Nussberger, L. Juillerat & H. R Brunner: Angiotensin-converting enzyme inhibition: discrepancy between anti-hypertensive effect and suppression of enzyme activity. J. Cardiovase. Pharmacol. 1989, 14, 53-59.
172. Vanhoutte, P. M., G. M. Rubanyi, V. M. Miller & D. S. Houston: Modulation of vascular smooth muscle contraction by the endothelium. Ann. Rev. Physiol. 1986, 48, 307-320.
173. Vankesteren, C. A. M., H. A. A. Vanheugten, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp & A. H. J. Danser: Angiotensin II mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J. Mol. Cell. Cardiol. 1997, 29, 2147-2157.
174. Webb, R. L., A. E. Navarrette, S. Davis & M. de Gasparo: Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious-telemetered spontaneously hypertensive rats (SHR). J. Hypertens. 1998 (in press).
175. Weber, K. T., C. G. Brilla, S. E. Campbell, E. Guarda, G. Zhou & K. Sriram: Myocardial Fibrosis - Role of Angiotensin-II and Aldosterone. Basic Res. Cardiol. 1993, 88, 107-124.
176. Weber, K. T., Y. Sun, L. C. Katwa & J. P. M. Cleutjens: Connective tissue - a metabolic entity [Review]. J. Mol. Cell. Cardiol. 1995, 27, 107-120.
177. Wolny, A., J. P. Clozel, J. Rein, P. Mory, P. Vogt, M. Turino, W. Kiowski & W. Fischli: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ. Res. 1997, 80, 219-227.
178. Wong, P. C., T. B. Barnes, A. T. Chiu, D. D. Christ, J. V. Duncia, W. F. Herblin & P. B. M. W. M. Timmermans: Losartan (Dup 753), an orally active nonpeptide angiotensin II receptor antagonist. Cardiovasc. Drug Rev. 1991, 9, 317-339.
179. Wright, J. W., L. T. Krebs, J. W. Stobb & J. W. Harding: Tthe angiotensin IV system - functional implications [Review]. Front. Neuroendocrinol. 1995, 16, 23-52.
180. Wu, L. L., A. Cox, C. J. Roe, M. Dziadek, M. E. Cooper & R. E. Gilbert: Transforming growth factor beta-1 and renal injury following subtotal nephrectomy in the rat - role of the renin-angiotensin system. Kidney Int. 1997, 51, 1553-1567.
181. Xie, M. H., F. Y. Liu, P. C. Wong, P. B. Timmermans & M. G. Cogan: Proximal nephron and renal effects of DuP 753, a non-peptide angiotensin II receptor antagonist. Kidner Int. 1990, 38, 473-479.
182. Yang, H., D. Lu, K. Yu & M. K. Raizada: Regulation of neuro-modulatory actions of angiotensin II in the brain neurons by the ras-dependent mitogen-activated protein kinase pathway. J. Neurosci. 1996, 16, 4047-4058.
183. Yamada, T., M. Horiuchi & V. J. Dzau: Angiotensin II type 2 receptor mediates programmed cell death. Proc. Natl. Acad. Sci. USA 1996, 93, 156-160.
184. Yamada, H., A. Masahiro & M. Horiuchi: Regulation of vascular development and differentiation by angiotensin type 2 receptor. Circulation 1997, 8, suppl. 1, I-478 (abstract 2668).
185. Yoshimura, Y., M. Karube, H. Aoki, T. Oda, N. Koyama, A. Nagai, Y. Akimoto, H. Hirano & Y. Nakamura: Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT(2) receptor subtype. Endocrinology. 1996, 137, 1204-1211.
186. Zhang, J. S. & R. E. Pratt: The AT(2) receptor selectively associates with G(i-alpha-2) and G(i-alpha-3) in the rat fetus. J. Biol. Chem. 1996, 271, 15026-15033.
187. Zhuo, J. L., R. Dean, D. Macgregor, D. Alcorn & F. A. O. Mendelsohn: Presence of angiotensin II AT(2) receptor binding sites in the adventitia of human kidney vasculature. Clin. Exp. Pharmacol Physiol. 1996, 23, S 147-S 154.
188. 2+ ATPase gene expression in renal hypertensive rats - dose-dependent effects of ace inhibition and AT(1)-receptor blockade. Cardiovas. Res. 1996, 31, 758-768.